Screener
Eligibility screening
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
41 US sites in AR, AZ, CA, CO +22
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.